Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
SingaporeIPO:
14 April 2023Website:
http://w2.cytomed.sgNext earnings report:
15 November 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 27 Sep 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
GDTC Latest News
SINGAPORE , Nov. 14, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced it will be presenting at The Benchmark Company's 12th Annual Discovery One-on-One Investor Conference to be held Thursday, December 7 th, 2023 at the New York Athletic Club in New York City. The conference offers emerging growth and dynamic publicly traded companies access to institutional and individual investors in a unique one-on-one format during which CytoMed Therapeutics will be participating in one-on-one meetings with investors and analysts throughout the day.
CytoMed Therapeutics is developing next-generation CAR-T cell therapies from γδ T cells for multiple solid tumor indications. The use of γδ T cells allows CytoMed to generate allogeneic, off-the-shelf cell therapies. By the end of 2024, CytoMed expects to have human data from two programs and pre-clinical data for its most promising program.
CytoMed Therapeutics (NASDAQ: GDTC ) stock is rocketing higher on Tuesday despite a lack of news concerning the company this morning. Instead of a press release of filing sending the shares higher, heavy trading is behind today's movement.
What type of business is CytoMed Therapeutics Limited?
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.
What sector is CytoMed Therapeutics Limited in?
CytoMed Therapeutics Limited is in the Healthcare sector
What industry is CytoMed Therapeutics Limited in?
CytoMed Therapeutics Limited is in the Biotechnology industry
What country is CytoMed Therapeutics Limited from?
CytoMed Therapeutics Limited is headquartered in Singapore
When did CytoMed Therapeutics Limited go public?
CytoMed Therapeutics Limited initial public offering (IPO) was on 14 April 2023
What is CytoMed Therapeutics Limited website?
https://w2.cytomed.sg
Is CytoMed Therapeutics Limited in the S&P 500?
No, CytoMed Therapeutics Limited is not included in the S&P 500 index
Is CytoMed Therapeutics Limited in the NASDAQ 100?
No, CytoMed Therapeutics Limited is not included in the NASDAQ 100 index
Is CytoMed Therapeutics Limited in the Dow Jones?
No, CytoMed Therapeutics Limited is not included in the Dow Jones index
When was CytoMed Therapeutics Limited the previous earnings report?
No data
When does CytoMed Therapeutics Limited earnings report?
The next expected earnings date for CytoMed Therapeutics Limited is 15 November 2024